Prevalence of mixed genotype hepatitis C virus infections in the UK as determined by genotype-specific PCR and deep sequencing

Journal of Viral Hepatitis

Volumn 25, Issue 5, 2018, Pages 524-534

  McNaughton, A L ^a,d   Sreenu, V B ^a   Wilkie, G ^a   Gunson, R ^b   Templeton, K ^c   Leitch, E C M ^a  

^a MRC UNIVERSITY OF GLASGOW CENTRE FOR VIRUS RESEARCH   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

^c Edinburgh Specialist Virology Centre   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

direct acting antivirals; HCV genotyping; hepatitis C virus; mixed genotype HCV infections; next generation sequencing

Indexed keywords

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEEP SEQUENCING; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; MAJOR CLINICAL STUDY; MALE; NEXT GENERATION SEQUENCING; NONHUMAN; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; UNITED KINGDOM; VIRUS LOAD; CLASSIFICATION; GENETICS; GENOTYPING TECHNIQUE; HEPACIVIRUS; HIGH THROUGHPUT SEQUENCING; ISOLATION AND PURIFICATION; MIDDLE AGED; MIXED INFECTION; VIROLOGY;

ADULT; COHORT STUDIES; COINFECTION; FEMALE; GENOTYPE; GENOTYPING TECHNIQUES; HEPACIVIRUS; HEPATITIS C; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PREVALENCE; UNITED KINGDOM;

EID: 85042208242     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12849     Document Type: Article

References (50)

1. Pham ST, Bull RA, Bennett JM, et al. Frequent multiple hepatitis C virus infections among injection drug users in a prison setting. Hepatology. 2010;52:1564-1572.
2. Du H, Qi Y, Hao F, et al. Complex patterns of HCV epidemic in Suzhou: evidence for dual infection and HCV recombination in East China. J Clin Virol. 2012;54:207-212.
3. Cunningham EB, Applegate TL, Lloyd AR, Dore GJ, Grebely J. Mixed HCV Infection and Reinfection in People Who Inject Drugs—Impact on Therapy. Nat Rev Gastroenterol Hepatol. 2015;12:218-30.
4. Blatt LM, Mutchnick MG, Tong MJ, et al. Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States. J Viral Hepat. 2000;7:196-202.
5. Butt S, Idrees M, Rehman IU, et al. Mixed genotype infections with hepatitis C virus, Pakistan. Emerg Infect Dis. 2011;17:1565.
6. Li H, Thomassen LV, Majid A, et al. Investigation of putative multisubtype hepatitis C virus infections in vivo by heteroduplex mobility analysis of core/envelope subgenomes. J Virol. 2008;82:7524-7532.
7. Schröter M, Feucht H-H, Zöllner B, Schäfer P, Laufs R. Multiple infections with different HCV genotypes: prevalence and clinical impact. J Clin Virol. 2003;27:200-204.
8. Buckton AJ, Ngui SL, Arnold C, et al. Multitypic hepatitis C virus infection identified by real-time nucleotide sequencing of minority genotypes. J Clin Microbiol. 2006;44:2779-2784.
9. EASL. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63:199-236.
10. Loulergue P, Mir O, Sogni P. Super-infection with genotype 4 hepatitis C virus patient treated for genotype 3 acute hepatitis C. AIDS. 2012;5:655-656.
11. McNaughton AL, Thomson EC, Templeton K, Gunson RN, Leitch ECM. Mixed genotype hepatitis C infections and implications for treatment. Hepatology. 2014;59:1209.
12. Humphreys I, Fleming V, Fabris P, et al. Full-length characterization of hepatitis C virus subtype 3a reveals novel hypervariable regions under positive selection during acute infection. J Virol. 2009;83:11456-11466.
13. Kolykhalov AA, Agapov EV, Blight KJ, Mihalik K, Feinstone SM, Rice CM. Transmission of Hepatitis C by intrahepatic inocuation with transcribed RNA. Science. 1997;277:570-574.
14. McLeish NJ, Witteveldt J, Clasper L, et al. Development and assay of RNA transcripts of enterovirus species A to D, rhinovirus species a to C, and human parechovirus: assessment of assay sensitivity and specificity of real-time screening and typing methods. J Clin Microbiol. 2012;50:2910-2917.
15. Kuiken C, Yusim K, Boykin L, Richardson R. The Los Alamos hepatitis C sequence database. Bioinformatics. 2005;21:379-384.
16. Edgar RC. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 2004;32:1792-1797.
17. Simmonds P. SSE: a nucleotide and amino acid sequence analysis platform. BMC Res Notes. 2012;5:50.
18. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol. 2011;28:2731-2739.
19. Kuiken C, Yusim K, Boykin L, Richardson R. The Los Alamos hepatitis C sequence database. Bioinformatics. 2004;21:379-384.
20. Benson DA, Cavanaugh M, Clark K, et al. GenBank. Nucleic Acids Res. 2013;41:D36-D42.
21. Jones DM, Domingues P, Targett-Adams P, McLauchlan J. Comparison of U2OS and Huh-7 cells for identifying host factors that affect hepatitis C virus RNA replication. J Gen Virol. 2010;91:2238-2248.
22. Sreenu VB, Nikolov G, Alotaibi S, et al. Tanoti. TANOTI: a rapid BLAST-guided read mapper for small, divergent genomes. http://www.bioinformatics.cvr.ac.uk/tanoti.php
23. Finney DJ. Probit Analysis: A Statistical Treatment of the Sigmoid Response Curve. Cambridge: Cambridge University Press; 1952.
24. Okamoto H, Okada S, Sugiyama Y, et al. Nucleotide sequence of the genomic RNA of hepatitis C virus isolated from a human carrier: comparison with reported isolates for conserved and divergent regions. J Gen Virol. 1991;72:2697-2704.
25. Jacka B, Lamoury F, Simmonds P, Dore GJ, Grebely J, Applegate T. Sequencing of the hepatitis C virus: a systematic review. PLoS ONE. 2013;8:e67073.
26. González V, Gomes-Fernandes M, Bascuñana E, et al. Accuracy of a commercially available assay for HCV genotyping and subtyping in the clinical practice. J Clin Virol. 2013;58:593-597.
27. Yun H, Kim D, Kim S, et al. High prevalence of HBV and HCV infection among intravenous drug users in Korea. J Med Virol. 2008;80:1570-1575.
28. van de Laar TJW, Molenkamp R, van den Berg C, et al. Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam. J Hepatol. 2009;51:667-674.
29. Herring BL, Page-Shafer K, Tobler LH, Delwart EL. Frequent hepatitis C virus superinfection in injection drug users. J Infect Dis. 2004;190:1396-1403.
30. Public Health England. Hepatitis C in the UK, 2015 report. 2015.
31. Grebely J, Pham ST, Matthews GV, et al. Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection. Hepatology. 2012;55:1058-1069.
32. Backmund M, Reimer J, Meyer K, Gerlach J, Zachoval R. Hepatitis C virus infection and injection drug users: prevention, risk factors, and treatment. Clin Infect Dis. 2005;40(Supplement 5):S330-S335.
33. Sacks-Davis R, Mcbryde E, Grebely J, Hellard M, Vickerman P, Sacks-Davis R. Many hepatitis C reinfections that spontaneously clear may be undetected: Markov-chain Monte Carlo analysis of observational study data. J R Soc Interface. 2015;12:20141197.
34. Sacks-Davis R, Grebely J, Dore GJ, et al. Hepatis C virus reinfection and spontaneous clearance of reinfection - the InC3 study. J Infect Dis. 2015;212:1407-1419.
35. Vickerman P, Grebely J, Dore GJ, et al. The more you look, the more you find: effects of hepatitis C virus testing interval on reinfection incidence and clearance and implications for future vaccine study design. J Infect Dis. 2012;205:1342-1350.
36. Osburn WO, Fisher BE, Dowd KA, et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology. 2010;138:315-324.
37. Grebely J, Prins M, Hellard M, et al. Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis. 2012;12:408-414.
38. De Angelis D, Hickman M, Yang S. Estimating long-term trends in the incidence and prevalence of opiate use/injecting drug use and the number of former users: back-calculation methods and opiate overdose deaths. Am J Epidemiol. 2004;160:994-1004.
39. McNaughton AL, Cameron D, Wignall-fleming EB, et al. Spatiotemporal reconstruction of the introduction of hepatitis C virus into scotland and its subsequent regional transmission. J Virol. 2015;89:11223-11232.
40. Sutton AJ, McDonald SA, Palmateer N, Taylor A, Hutchinson SJ. Estimating the variability in the risk of infection for hepatitis C in the Glasgow injecting drug user population. Epidemiol Infect. 2012;140:2190-2198.
41. Harris HE, Eldridge KP, Harbour S, Alexander G, Teo C-GG, Ramsay ME. Does the clinical outcome of hepatitis C infection vary with the infecting hepatitis C virus type? J Viral Hepat. 2007;14:213-220.
42. Zein NN. Clinical significance of hepatitis C virus genotypes clinical significance of hepatitis C virus genotypes. Cinical Microbiol Rev. 2000;13:223-235.
43. Abdelrahman T, Hughes J, Main J, McLauchlan J, Thurz M, Thomson E. Next generation sequencing sheds light on the natural history of hepatitis C infection in patients that fail treatment. Hepatology. 2015;61:88-97.
44. Grebely J, Conway B, Raffa JD, Lai C, Krajden M, Tyndall MW. Hepatitis C virus reinfection in injection drug users. Hepatology. United States. 2006;44:1139-1145.
45. Dore GJ, Micallef J. Low incidence of HCV reinfection: exposure, testing frequency, or protective immunity? Hepatology. 2007;45:1330.
46. Blackard JT, Kemmer N, Sherman KE. Extrahepatic replication of HCV: insights into clinical manifestations and biological consequences. Hepatology. 2006;44:15-22.
47. Thomson E, Ip CLC, Badhan A, et al. Comparison of next-generation sequencing technologies for comprehensive assessment of full-length hepatitis C viral genomes. J Clin Microbiol. 2016;54:2470-2484.
48. Jabara CB, Jones CD, Roach J, Anderson JA, Swanstrom R. Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID. Proc Natl Acad Sci USA. 2011;108:20166-20171.
49. McElroy K, Thomas T, Luciani F. Deep sequencing of evolving pathogen populations: applications, errors, and bioinformatic solutions. Microb Inform Exp. 2014;4:1.
50. Kuiken C, Combet C, Bukh J, et al. A comprehensive system for consistent numbering of HCV sequences, proteins and epitopes. Hepatology. 2006;44:1355-1361.